Shernan G. Holtan: New findings from the Blood and Marrow Transplant Clinical Trials Network 1703 trial
Shernan G.Holtan, Chief of the Blood and Marrow Transplant Program at Roswell Park, shared a recent article on X:
“New findings from the Blood and Marrow Transplant Clinical Trials Network 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported GVHD symptom burden vs Tac/MTX in the first year after transplant.
Congrats, team.”
Authors: Shernan G. Holtan, Javier Bolaños-Meade, Monzr M. Al Malki, Juan Wu, Ran Reshef, Andrew R. Rezvani, Brian C. Shaffer, Melhem M. Solh, Janny M. Yao, Lyndsey Runaas, Hany Elmariah, Karilyn T. Larkin, Najla El Jurdi, Mahasweta Gooptu, Alison W. Loren, Aric C. Hall, Amin M. Alousi, Omer Jamy, William Clark, Leslie Kean, Ami S. Bhatt, Miguel-Angel Perales, Kristy Applegate, Yvonne Adeduni Efebera, Eric Leifer, Richard J. Jones, Mary M. Horowitz, Deborah Mattila, Wael Saber, Mehdi Hamadani and Michael J. Martens
More posts featuring Shernan G. Holtan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023